Published in Nat Rev Cancer on January 01, 2006
Immunity, inflammation, and cancer. Cell (2010) 28.27
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 7.58
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One (2009) 3.86
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov (2008) 3.25
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer (2007) 3.12
Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95
MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol (2015) 2.85
Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature (2010) 2.79
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 2.62
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A (2012) 2.61
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A (2009) 2.57
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst (2009) 2.50
The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 2.48
Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 2.44
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun (2007) 2.44
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
Macrophage activation by endogenous danger signals. J Pathol (2008) 2.38
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech (2008) 2.34
Mechanistic links between COPD and lung cancer. Nat Rev Cancer (2013) 2.28
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity (2012) 2.23
The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res (2011) 2.22
Positive psychology in cancer care: bad science, exaggerated claims, and unproven medicine. Ann Behav Med (2010) 2.19
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14
Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 2.13
IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol (2010) 2.12
ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med (2010) 2.09
An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One (2010) 2.08
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev (2009) 1.95
Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell (2009) 1.95
Dynamic, long-term in vivo imaging of tumor-stroma interactions in mouse models of breast cancer using spinning-disk confocal microscopy. Cold Spring Harb Protoc (2011) 1.95
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat (2007) 1.95
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet (2014) 1.94
Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis. PLoS One (2009) 1.93
Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol (2011) 1.88
The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol (2012) 1.86
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
An innate immune response of blood cells to tumors and tissue damage in Drosophila. Dis Model Mech (2008) 1.84
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med (2010) 1.81
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Imaging angiogenesis and the microenvironment. APMIS (2008) 1.77
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol (2013) 1.75
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology (2008) 1.68
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun (2008) 1.66
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64
TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest (2007) 1.63
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer (2008) 1.62
Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci U S A (2008) 1.62
Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol (2008) 1.59
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
Genomic spectra of biliary tract cancer. Nat Genet (2015) 1.58
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56
Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology (2010) 1.56
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia (2009) 1.55
Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One (2008) 1.55
Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol (2008) 1.52
Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res (2009) 1.51
Prognostic value of PLR in various cancers: a meta-analysis. PLoS One (2014) 1.50
Integrative analysis reveals the direct and indirect interactions between DNA copy number aberrations and gene expression changes. Bioinformatics (2008) 1.49
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
The Basis of Oncoimmunology. Cell (2016) 1.47
VEGFR1-activity-independent metastasis formation. Nature (2009) 1.47
Memory CD8+ T cell differentiation. Ann N Y Acad Sci (2010) 1.47
The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest (2007) 1.46
Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res (2009) 1.45
Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol (2012) 1.45
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Cancer: an inflammatory link. Nature (2004) 3.88
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev (2008) 2.85
Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol (2009) 2.84
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol (2006) 1.95
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res (2005) 1.84
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res (2004) 1.71
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol (2003) 1.63
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
MMP9 potentiates pulmonary metastasis formation. Cancer Cell (2002) 1.57
Inflammation, proteases and cancer. Eur J Cancer (2006) 1.52
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res (2012) 1.50
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40
Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech (2010) 1.35
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn (2007) 1.35
The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia (2010) 1.33
Soluble mediators of inflammation during tumor development. Adv Cancer Res (2005) 1.24
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C. J Am Chem Soc (2006) 1.09
Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol (2013) 1.07
Inflaming gastrointestinal oncogenic programming. Cancer Cell (2008) 1.07
Early neoplastic progression is complement independent. Neoplasia (2005) 1.07
Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer (2011) 1.04
NF-kappaB-mediated induction of p21(Cip1/Waf1) by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol Cancer Res (2003) 1.02
TIMP-1 alters susceptibility to carcinogenesis. Cancer Res (2004) 1.01
Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 0.99
Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc (2006) 0.99
Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation (2002) 0.97
RECKing MMP function: implications for cancer development. Trends Cell Biol (2002) 0.96
Delineating protease functions during cancer development. Methods Mol Biol (2009) 0.93
Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. Mol Cancer Res (2007) 0.91
IKKalpha at the crossroads of inflammation and metastasis. Cell (2007) 0.89
Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. Cancer Res (2007) 0.89
Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem (2007) 0.89
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Res (2010) 0.89
MR imaging of tumor-associated macrophages. Oncoimmunology (2012) 0.88
Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev (2013) 0.87
Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem (2008) 0.86
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
Protective role of cathepsin L in mouse skin carcinogenesis. Mol Carcinog (2011) 0.86
Three-dimensional visualization of blood and lymphatic vasculature in tissue whole mounts using confocal microscopy. Curr Protoc Cytom (2005) 0.83
Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. Int J Cancer (2010) 0.83
Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev (2008) 0.81
Optical imaging of the peri-tumoral inflammatory response in breast cancer. J Transl Med (2009) 0.81
Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. J Mammary Gland Biol Neoplasia (2014) 0.79
Histamine restricts cancer: nothing to sneeze at. Nat Med (2011) 0.78
Myeloid Cells as Targets for Therapy in Solid Tumors. Cancer J (2015) 0.78
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther (2006) 0.76
AACR Cancer Progress Report 2016. Clin Cancer Res (2016) 0.75
Some DCs are "B"etter. Immunity (2013) 0.75
Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. US Oncol (2009) 0.75
Poker face no more: cancer recurrence reveals its hand. Nat Med (2013) 0.75
Multiplexed immunohistochemistry image analysis using sparse coding. Conf Proc IEEE Eng Med Biol Soc (2017) 0.75